Physiologically, it is known that LysRS binds to the 67-kDa laminin receptor (67LR), a target for antimetastatic therapeutics [32], in the plasma membrane and enhances cell migration that causes cancer metastasis. This evidence concerns the gene KARS1 and cancer.